Skip to content

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-S)

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-S). This study is ongoing, but not recruiting participants. A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis (IXORA-Q). Have chronic plaque psoriasis based on a diagnosis of chronic plaque psoriasis for at least 6 months before baseline. A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-S). This study is ongoing, but not recruiting participants.

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-S) 2With Moderate-to-Severe Plaque Psoriasis. A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis.

A 52-week Multicenter, Randomized, Blinded, Parallel-group Study Comparing The Efficacy And Safety Of Ixekizumab To Ustekinumab In Patients With Moderate-to-severe Plaque Psoriasis

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-S) 3

A Study Of Ixekizumab (ly2439821) In Participants With Moderate-to-severe Plaque Psoriasis